Document detail
ID
doi:10.1038/s41593-021-00926-1...
Author
Jan Wenzel Josephine Lampe Helge Müller-Fielitz Raphael Schuster Marietta Zille Kristin Müller Markus Krohn Jakob Körbelin Linlin Zhang Ümit Özorhan Vanessa Neve Julian U. G. Wagner Denisa Bojkova Mariana Shumliakivska Yun Jiang Anke Fähnrich Fabian Ott Valentin Sencio Cyril Robil Susanne Pfefferle Florent Sauve Caio Fernando Ferreira Coêlho Jonas Franz Frauke Spiecker Beate Lembrich Sonja Binder Nina Feller Peter König Hauke Busch Ludovic Collin Roberto Villaseñor Olaf Jöhren Hermann C. Altmeppen Manolis Pasparakis Stefanie Dimmeler Jindrich Cinatl Klaus Püschel Matija Zelic Dimitry Ofengeim Christine Stadelmann François Trottein Ruben Nogueiras Rolf Hilgenfeld Markus Glatzel Vincent Prevot Markus SchwaningeEditor
Nature Neuroscience
Category
Neurosciences
Year
2022
listing date
10/27/2022
Keywords
pathology covid-19 ripk nemo covid sars-cov-2 Blood–brain barrier Central nervous system infectionsAbstract
Coronavirus disease 2019 (COVID-19) can damage cerebral small vessels and cause neurological symptoms.
Here we describe structural changes in cerebral small vessels of patients with COVID-19 and elucidate potential mechanisms underlying the vascular pathology.
In brains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals and animal models, we found an increased number of empty basement membrane tubes, so-called string vessels representing remnants of lost capillaries.
We obtained evidence that brain endothelial cells are infected and that the main protease of SARS-CoV-2 (Mpro) cleaves NEMO, the essential modulator of nuclear factor-κB.
By ablating NEMO, Mpro induces the death of human brain endothelial cells and the occurrence of string vessels in mice.
Deletion of receptor-interacting protein kinase (RIPK) 3, a mediator of regulated cell death, blocks the vessel rarefaction and disruption of the blood–brain barrier due to NEMO ablation.
Importantly, a pharmacological inhibitor of RIPK signaling prevented the Mpro-induced microvascular pathology.
Our data suggest RIPK as a potential therapeutic target to treat the neuropathology of COVID-19.
Jan Wenzel, Josephine Lampe, Helge Müller-Fielitz, Raphael Schuster, Marietta Zille, Kristin Müller, Markus Krohn, Jakob Körbelin, Linlin Zhang, Ümit Özorhan, Vanessa Neve, Julian U. G. Wagner, Denisa Bojkova, Mariana Shumliakivska, Yun Jiang, Anke Fähnrich, Fabian Ott, Valentin Sencio, Cyril Robil, Susanne Pfefferle, Florent Sauve, Caio Fernando Ferreira Coêlho, Jonas Franz, Frauke Spiecker, Beate Lembrich, Sonja Binder, Nina Feller, Peter König, Hauke Busch, Ludovic Collin, Roberto Villaseñor, Olaf Jöhren, Hermann C. Altmeppen, Manolis Pasparakis, Stefanie Dimmeler, Jindrich Cinatl, Klaus Püschel, Matija Zelic, Dimitry Ofengeim, Christine Stadelmann, François Trottein, Ruben Nogueiras, Rolf Hilgenfeld, Markus Glatzel, Vincent Prevot , Markus Schwaninge, 2022, The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells, Nature Neuroscience
A Novel MR Imaging Sequence of 3D-ZOOMit Real Inversion-Recovery Imaging Improves Endolymphatic Hydrops Detection in Patients with Ménière Disease
ménière disease p < detection imaging sequences 3d-zoomit 3d endolymphatic real tse reconstruction ir inversion-recovery hydrops ratio
